CODX - Company ID 0001692415
The table below shows Co-Diagnostics, Inc.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q1 2025 | Q1 2024 | Q1 2023 | Q1 2022 | Q1 2021 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$7.85M | -$8.75M | -$8.49M | -$5.92M | $7.81M | $12.27M |
| Capital expenditure | $142.02K | $91.91K | $402.29K | $179.94K | $396.60K | $139.56K |
| Investing cash flow | -$142.02K | $7.36M | $16.67M | -$10.21M | $858.67K | $2.39M |
| Dividends paid | - | - | - | - |
Co-Diagnostics, Inc. reported operating cash flow of -$29.14M for fiscal year 2025. That is up 0.1% from -$29.16M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow declined from -$1.31M (FY 2016) to -$29.14M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| - |
| Stock buybacks | - | - | - | $482.20K | - | - |
| Financing cash flow | $4.33M | $354.75K | - | -$482.20K | $150.00K | $148.98K |